Marked decrease of serum Ca 125 levels after Denver shunt placement in a patient with cirrhosis and refractory ascites.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to D Gui.
Explore the source record for details and available documents.
BACKGROUND: A potential approach to the treatment of morbid obesity is reduction of gastric emptying to achieve satiety. Botulinum toxin A (Btx-A) is a long-acting inhibitor of acetylcholine-mediated peristalsis, which is mainly responsible for gastric motility. AIM: To investigate whether botulinum toxin A, injected in the antrum of obese patients, delays gastric emptying. METHODS: In a double_blind study, 18 healthy obese subjects (body mass index >30) were randomized into three groups (BTX133, BTX200 and Saline); they received Btx-A133U, Btx-A200U, or saline under endoscopic control. Gastric emptying was tested by scintigraphy before and 10 days after treatment. Body weight variations and appetite sensation were recorded after 5 weeks. RESULTS: Fourteen patients completed the study. The botulinum toxin A-treated groups showed weight reduction, which was not statistically significant. The effects on gastric emptying were variable. Most of the botulinum toxin A treated patients reported a reduced appetite. CONCLUSION: This pilot clinical trial suggests potential activity of botulinum toxin A for the manipulation of appetite.
BACKGROUND: Infection of polytetrafluoroethylene (ePTFE) prostheses for abdominal incisional hernia is a rare but serious complication that often makes meshes removal necessary. Instead serous collections (seromas) without signs of infection don't require surgical removal. Differential diagnosis between infected and non-infected fluid collections is difficult and sometimes impossible before surgical exploration. METHODS: We describe a new sign observed in two patients who underwent abdominal computed tomography for evaluation of a fluid collection without clear signs of prosthesis infection, complicating abdominal wall repair for incisional hernia in which an ePTFE mesh was used. In both patients an alteration of the mesh profile was demonstrated on imaging, and in both patients prostheses resulted infected at surgical exploration and at microbiological examination after removal. The sign we observed is not evident in computed tomography images performed in cases of seromas. CONCLUSIONS: We discuss the possible mechanism of this finding and propose that this sign may be due to a "rejection" of the infected prosthesis from the surrounding neo-formed fibrous and inflammatory tissue.
Since 1980, botulinum toxin has been employed for the treatment of various voluntary muscle spastic disorders in the fields of neurology and ophthalmology. More recently, botulinum toxin has been proved to be effective in the therapy of dyskinetic smooth muscle disorders of the gastrointestinal tract. Achalasia and anal fissure are the gastrointestinal disorders in which botulinum toxin therapy has been most extensively investigated. Botulinum toxin is the best treatment option for achalasia in patients whose condition makes them unfit for pneumatic dilation or surgery. In anal fissure, botulinum toxin is highly effective and may become the treatment of choice. In the future, botulinum toxin application in the gastrointestinal tract will be extended to many other gastrointestinal disorders, such as non-achalasic motor disorders of the oesophagus, dysfunction of Oddi's sphincter, achalasia of the internal anal sphincter and others. This article describes the mechanism of action, rationale of employment, indications and side-effects of botulinum toxin application in smooth muscle disorders of the gastrointestinal tract, and compares the results of different techniques of botulinum toxin therapeutic application.
Explore the source record for details and available documents.
During laparoscopic cholecystectomy for cholelithiasis in a 40-year-old woman, we came upon a case of incidentally discovered left-sided gallbladder (LSG). Two anatomic variants of LSG are known: (a) "true LSG," in which, according to Gross, an accessory gallbladder originates from the left hepatic duct (LHD), the right embryonic bud is readsorbed, and the cystic duct joins either the CBD from the left or the LHD directly. Otherwise, a normal right-sided gallbladder adheres to the inferior left hepatic lobe, and the cystic duct joins the CBD from the right side (as in our case); (b) gallbladder under the fourth hepatic segment, medial to a right-sided round ligament, probably resulting from a prenatal obliteration of the right umbilical vein. Left-sided gallbladder is a paraphysiologic condition that when identified before surgery, must be studied by CT or MRI, when incidentally discovered during surgery must be promptly recognized by the surgeon, who must be aware of the unpredictable confluence of the cystic duct into the CBD. The following operative precautions are useful for avoiding a lesion of the CBD: The surgeon should start dissection of Calot's triangle as close as possible to the gallbladder margin, prepare and clip the cystic duct as close as possible to the infundibulum, and a 30 degrees angled telescope. If in doubt, the surgeon should perform an intraoperative cholangiography.
BACKGROUND: Botulinum toxin induces healing in patients with idiopathic anal fissure. METHODS: Fifty patients affected by posterior anal fissure were treated with 20 units of botulinum toxin, injection in the internal anal sphincter on each side of the posterior midline (group I) or on each side of the anterior midline (group II). RESULTS: At 2 months evaluation, a healing scar was observed in 15 patients of group I and in 22 patients of group II(P = 0.025). Resting anal pressure was significantly different from the baseline values at 1-month as well as at 2-month check-ups in both groups, but the values were significantly lower in patients of group II. CONCLUSIONS: The intersite comparison revealed that anterior injection of the internal anal sphincter resulted in improved lowering of resting anal pressure and produced an earlier healing scar.
BACKGROUND: Botulinum toxin is a powerful, long-acting inhibitor of muscular contractions in both voluntary and smooth muscle. It acts by blocking the release of the neurotransmitter acetylcholine. In the stomach, propulsive contractions of the antrum are necessary for the gastric contents to pass into the duodenum. AIMS: To investigate whether intramuscular injections of botulinum toxin type A into the gastric antrum of rats would cause a reduction in food intake and hence body weight, by inhibition of gastric emptying. MATERIALS AND METHODS: This was a prospective, randomized, 3-way parallel group study in rats. The first group was anaesthetized, laparotomized and given 20 U of botulinum toxin type A by intramuscular injection into the gastric antrum (botulinum toxin type A group, n=14). The second group was anaesthetized, laparotomized and injected with saline (sham group, n=14) and the third group did not have any intervention (control group, n=5). Food intake was measured daily for 7 weeks and body weight was measured daily for 10 weeks. RESULTS: There was a significant difference in loss of body weight between the two treated groups (14.0 +/- 8.2% botulinum toxin type A group, 4.4 +/- 2.7% sham group; P < 0.001). Further, the time to reach the weight nadir was significantly longer in the botulinum toxin type A group (8.7 +/- 3.9 days) compared with the sham group (5.3 +/- 3.8 days; P < 0.04). There were no significant differences between the sham and control groups for any of the body weight parameters. The minimum dietary intake was significantly lower in the botulinum toxin type A group than in the sham group (37.8 +/- 21.8% of the basal value in the botulinum toxin type A group, vs. 65.5 +/- 32.0 in the sham group, P < 0.05). In addition, the time to reach the nadir was significantly prolonged (8.2 +/- 3.5 days, botulinum toxin type A group vs. 4.9 +/- 1.7 days, sham group, P < 0.001). CONCLUSIONS: The parallel reduction of body weight and food intake in botulinum toxin type A treated animals is consistent with a long lasting inhibition of the antral pump. This is probably due to slowed gastric emptying leading to early satiety. Patients with morbid obesity might benefit from endoscopic injections of botulinum toxin type A into the stomach wall.
BACKGROUND AND METHODS: Lateral internal sphincterotomy, the most common treatment for chronic anal fissure, may cause permanent injury to the anal sphincter, which can lead to fecal incontinence. We compared two nonsurgical treatments that avert the risk of fecal incontinence. We randomly assigned 50 adults with symptomatic chronic posterior anal fissures to receive treatment with either a total of 20 U of botulinum toxin injected into the internal anal sphincter on each side of the anterior midline or 0.2 percent nitroglycerin ointment applied twice daily for six weeks. RESULTS: After two months, the fissures were healed in 24 of the 25 patients (96 percent) in the botulinum-toxin group and in 15 of the 25 (60 percent) in the nitroglycerin group (P=0.005). No patient in either group had fecal incontinence. At some time during treatment, five patients in the nitroglycerin group had transient, moderate-to-severe headaches that were related to treatment. None of the patients in the botulinum-toxin group reported adverse effects. Ten patients who did not have a response to the assigned treatment - 1 in the botulinum-toxin group and 9 in the nitroglycerin group - crossed over to the other treatment; the fissures subsequently healed in all 10 patients. There were no relapses during an average of about 15 months of follow-up. CONCLUSIONS: Although treatment with either topical nitroglycerin or botulinum toxin is effective as an alternative to surgery for patients with chronic anal fissure, botulinum toxin is the more effective nonsurgical treatment.
BACKGROUND: Chronic anal fissure is a tear in the lower half of the anal canal that is maintained by contraction of the internal anal sphincter. Sphincterotomy, the most widely used treatment, is a surgical procedure that permanently weakens the internal sphincter and may lead to anal deformity and incontinence. METHODS: We conducted a double-blind, placebo-controlled study of botulinum toxin for the treatment of chronic anal fissure in 30 consecutive symptomatic adults. All the patients received two injections (total volume, 0.4 ml) into the internal anal sphincter; the treated group (15 patients) received 20 U of botulinum toxin A, and the control group (15 patients) received saline. Success was defined as healing of the fissure (formation of a scar), and symptomatic improvement was defined as the presence of a persistent fissure without symptoms. RESULTS: After two months, 11 patients in the treated group and 2 in the control group had healed fissures (P=0.003); 13 in the treated group and 4 in the control group had symptomatic relief (P=0.003). The maximal voluntary pressures were similar to those at base line in both groups, and the resting anal pressure was reduced by 25 percent in the treated group but not in the control group. Three patients in the control group later underwent sphincterotomy, and 10 received botulinum-toxin injections (20 U). Of the latter, seven had healed fissures after two months; the other three left the study and underwent surgery. Four patients in the treated group were later re-treated (with 25 U of botulinum toxin); all had healed fissures after two months. One patient in the control group had temporary flatus incontinence after treatment with botulinum toxin. No relapses occurred during an average of 16 months of follow-up. CONCLUSIONS: Local infiltration of botulinum toxin into the internal anal sphincter is an effective treatment of chronic anal fissure.
OBJECTIVE: To investigate the effects of two different dosage regimens of botulinum toxin to induce healing in patients with idiopathic anal fissure. SUMMARY BACKGROUND DATA: Chronic anal fissure is maintained by contraction of the internal anal sphincter. Sphincterotomy, which is successful in 85% to 95% of patients, permanently weakens the sphincter and therefore might be associated with anal deformity and incontinence. METHODS: Fifty-seven consecutive outpatients were evaluated. Type A botulinum toxin was injected into the internal anal sphincter. RESULTS: Patients were divided into two treatment groups based on the number of botulinum toxin units injected. Patients in the first group were treated with 15 units and retreated with 20 units. Patients in the second group were treated with 20 units and retreated with 25 units. Two months after treatment, 10 patients in the first group and 23 patients in the second group had a healing scar. Symptomatic improvement was observed in 13 patients in the first group and in 24 patients in the second group. Statistical analysis showed that resting anal pressure varied from baseline values as a function of treatment; in contrast, the treatment had no effect on maximum voluntary pressure. Long-term healing was achieved in 13 patients in the first group and in all patients in the second group who underwent a complete treatment. CONCLUSIONS: Botulinum toxin is safe and effective in the treatment of anal fissure. It is less expensive and easier to perform than surgical treatment. No adverse effects resulted from injections of the toxin. The higher dosage is effective in producing long-term healing without complications.
Studies have been made on baked Fructus Auantii Immaturus with bran of different storage periods by physico-chemical and TLC identification methods. The contents of synephrine were determined by HPLC, and the volatile oil and soaked constituents were analysed. The experimental result shows that the contents of samples get reduced as the storage is prolonged.
OBJECTIVES: To identify factors that influence mortality in patients who are affected by intra-abdominal infections (IAIs) and to make a comparison among three different scoring systems: the Acute Physiology and Chronic Health Evaluation (APACHE) II score, the sepsis score of Elebute and Stoner, and the Mannheim peritonitis index. DESIGN: Case series. SETTING: Both primary and referral hospital care. PATIENTS: The hospital records of 604 patients who consecutively underwent emergency operations for unequivocal IAIs, both spontaneous and postoperative, from 1981 to 1993, were retrospectively reviewed. Patients with IAIs that were related to peritoneal dialysis or infected ascites, those patients who were affected by primary peritonitis from a distant site, and those patients who underwent operations for acute appendicitis or acute cholecystitis without peritoneal contamination were excluded from the study. Univariate and multivariate analyses were used to calculate the prognostic significance of the following variables: age (< or = 70 vs > 70 years); sex; type (spontaneous vs postoperative) and extent (localized vs diffuse) of infection; preoperative serum levels of albumin, cholesterol, and hemoglobin; preoperative total lymphocyte count; amount of intraoperative blood loss; presence of preoperative organ impairment; the APACHE II score; the sepsis score of Elebute and Stoner; and the Mannheim peritonitis index. MAIN OUTCOME MEASURE: Death was the outcome variable that was studied. RESULTS: Multivariate logistic regression analysis showed that the APACHE II score, the Mannheim peritonitis index, hypoalbuminemia, hypocholesterolemia, and preoperative organ impairment were independent predictors of death. CONCLUSIONS: Results showed a significant dominance of host-related factors over the type and source of infection on the prognosis of patients with IAIs. Both the APACHE II score and the Mannheim peritonitis index correctly graded IAI severity and were strongly and independently associated with the outcome; however, the latter score has the advantage of being easier to calculate.
OBJECTIVE: To evaluate the additional information provided by the determination of cholesterolemia to the Acute Physiology and Chronic Health Evaluation (APACHE) II score. DESIGN: Retrospective evaluation of patients admitted to the intensive care unit (ICU). SETTING: ICUs in a university hospital. PATIENTS: 638 consecutive critically ill surgical patients. INTERVENTIONS: Surgical and medical therapy according to clinical status. MEASUREMENTS AND MAIN RESULTS: Two indices were devised: DELCUPOS and DELCUNEG (cubed absolute value of the difference between measure cholesterol and the value of 190 mg/dl when cholesterolemia was, respectively, over and under 190 mg). The first estimation of cholesterolemia was taken upon admission to the ICU. The APACHE II score was computed from teh worst values obtained during the first 24h of the ICU stay, including the pre-operative period for patients transferred from the operating theatre. Mortality (24.4%) over the whole time of hospitalization has been considered. A stepwise linear logistic regression on APACHE II, DELCUPOS, DELCUNEG, and on interactions among these three factors has been carried out. A U-shaped relationship between cholesterolemia and morality was demonstrated. The significance of DELCUPOS (p = 0.0021) and DELCUNEG (p = 0.0002), considered together with the APACHE II score, has demonstrated an additive information content with respect to the APACHE score for the prediction of mortality. CONCLUSION: Both hyper- and hypocholesterolemia have a highly significant relationship to mortality. Cholesterolemia improves the prognostic power of the APACHE II score. This result could be used to create a more powerful prognostic index.
Retroperitoneal abscess with multiple organ failure, after traumatic duodenal rupture followed by dehiscence of duodenal sutures, is a condition associated with a very high mortality. We report on a case treated by retroperitoneal laparostomy, a technique proposed as treatment for pancreatic abscess after an acute necrotizing pancreatitis. The retroperitoneal laparostomy creates a wide open cavity in a gravity-favorable position, allowing drainage and daily debridement of necrotic collections.
New and future indications for the treatment of disorders of the alimentary tract using local injections of botulinum toxin are reviewed. Clinical experience shows that overactive smooth muscle sphincters may be weakened to treat disorders such as achalasia or chronic anal fissure. By contrast, injections placed into the sphincter of Oddi have proven less effective for postcholecystectomy pain syndrome. Experimental evidence suggests that food intake may be reduced by weakening the distal stomach with botulinum toxin. This approach may possibly lead to the treatment of obesity. There are some new possible indications for the use of botulinum toxin on the alimentary tract, and infantile hypertrophic pyloric stenosis seems to be the most promising new development.
Botulinum toxin can chemically denervate striated muscle. Botulinum toxin A (15 U) was used to treat ten patients with chronic anal fissure by injection in the internal sphincter. In seven patients, the lesion healed at 2 months after treatment; one relapsed at 3 months. In one patient the lesion healed at 1 month, but partly relapsed a month later. Mild faecal incontinence lasting for 1 day was observed in one patient. We propose that botulinum toxin injections in the internal anal sphincter be considered an alternative approach to surgical therapy of anal fissure.
OBJECTIVE: To compare the results of closed treatment (CT) with the results of open treatment (OT) that uses laparostomy and marsupialization of the lesser sac in patients affected by secondary pancreatic infections. DESIGN: Retrospective cohort study. SETTING: Both primary and referral hospital care. PATIENTS: Forty-two patients undergoing emergency operations for unequivocal secondary pancreatic infections (infected pancreatic necrosis [n = 26] and pancreatic abscess [n = 14]) were retrospectively divided into two treatment groups on the basis of the operative treatment: conventional CT (n = 24) (1981 through 1986) and OT by laparostomy and marsupialization of the lesser sac (n = 18) (1987 through 1991). The OT and CT groups were homogeneous regarding demographic characteristics, mean APACHE (Acute Physiology and Chronic Health Evaluation) II score (17.1 +/- 6.0 vs 17.9 +/- 7.2, respectively; P value was not significant), and distribution of patients according to the type of pancreatic infection (infected pancreatic necrosis [13 vs 15, respectively] and pancreatic abscess [five vs nine, respectively]). The use of medical supportive care, including total parenteral nutrition and heavy doses of broad-spectrum antibiotics, was similar in both groups. MAIN OUTCOME MEASURES: Surgical complications; recurrent or persistent sepsis; postoperative death. RESULTS: The incidence of major surgical complications was 55.5% and 8.3% in OT and CT groups, respectively (P = .001). In OT and CT groups, signs of recurrent or persistent sepsis were observed in 5.6% vs 41.7% of the patients, respectively (P = .008): 7.7% vs 46.7% in patients with infected pancreatic necrosis (P = .02) and 0% vs 33.3% in patients with pancreatic abscess (P value was not significant). Overall mortality rates were 22.2% and 28.5% in the OT and CT groups, respectively (P value was not significant). The mortality rates due to recurrent or persistent sepsis in the OT and CT groups were 5.5% and 29.1%, respectively (P = .03). CONCLUSIONS: Although the frequency of major surgical complications after OT is significantly higher than that observed after CT, open drainage by means of laparostomy and marsupialization of the lesser sac controls pancreatic infection better, thus reducing mortality rate due to persistent or recurrent sepsis.